Sarepta Therapeutics (SRPT) Competitors $18.67 +0.51 (+2.81%) As of 10:14 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRPT vs. CTMX, EDIT, GRFS, RVMD, RYTM, LEGN, ABVX, RNA, AXSM, and NUVLShould you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include CytomX Therapeutics (CTMX), Editas Medicine (EDIT), Grifols (GRFS), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Abivax (ABVX), Avidity Biosciences (RNA), Axsome Therapeutics (AXSM), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Sarepta Therapeutics vs. Its Competitors CytomX Therapeutics Editas Medicine Grifols Revolution Medicines Rhythm Pharmaceuticals Legend Biotech Abivax Avidity Biosciences Axsome Therapeutics Nuvalent CytomX Therapeutics (NASDAQ:CTMX) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation. Is CTMX or SRPT more profitable? CytomX Therapeutics has a net margin of 34.04% compared to Sarepta Therapeutics' net margin of -2.34%. CytomX Therapeutics' return on equity of 158.70% beat Sarepta Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CytomX Therapeutics34.04% 158.70% 36.04% Sarepta Therapeutics -2.34%-1.03%-0.37% Does the media refer more to CTMX or SRPT? In the previous week, Sarepta Therapeutics had 8 more articles in the media than CytomX Therapeutics. MarketBeat recorded 11 mentions for Sarepta Therapeutics and 3 mentions for CytomX Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.01 beat CytomX Therapeutics' score of 0.78 indicating that Sarepta Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Sarepta Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate CTMX or SRPT? CytomX Therapeutics presently has a consensus target price of $5.75, indicating a potential upside of 170.46%. Sarepta Therapeutics has a consensus target price of $43.50, indicating a potential upside of 133.46%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe CytomX Therapeutics is more favorable than Sarepta Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytomX Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Sarepta Therapeutics 6 Sell rating(s) 15 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.07 Which has more risk & volatility, CTMX or SRPT? CytomX Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Which has better valuation & earnings, CTMX or SRPT? Sarepta Therapeutics has higher revenue and earnings than CytomX Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytomX Therapeutics$138.10M2.54$31.87M$0.563.80Sarepta Therapeutics$1.90B0.96$235.24M-$0.87-21.42 Do institutionals and insiders have more ownership in CTMX or SRPT? 67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 6.6% of CytomX Therapeutics shares are owned by insiders. Comparatively, 7.6% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryCytomX Therapeutics beats Sarepta Therapeutics on 9 of the 16 factors compared between the two stocks. Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRPT vs. The Competition Export to ExcelMetricSarepta TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.78B$3.10B$5.77B$9.76BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-20.9520.8683.0526.39Price / Sales0.96391.41527.23108.99Price / Cash7.4743.5325.7028.92Price / Book1.348.1011.006.58Net Income$235.24M-$53.35M$3.28B$265.84M7 Day Performance3.12%-0.29%-0.19%-0.26%1 Month Performance17.12%9.18%8.33%5.82%1 Year Performance-86.21%10.11%53.31%22.47% Sarepta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRPTSarepta Therapeutics4.7779 of 5 stars$18.67+2.8%$43.50+133.0%-86.6%$1.82B$1.90B-21.451,372Positive NewsCTMXCytomX Therapeutics4.2587 of 5 stars$2.00-5.7%$5.75+187.5%+76.3%$329.83M$141.10M3.57170EDITEditas Medicine4.0343 of 5 stars$2.72-2.9%$5.10+87.5%-34.0%$244.58M$38.90M-0.95230News CoverageAnalyst ForecastGRFSGrifols3.9358 of 5 stars$9.82-3.3%$10.30+4.9%+3.6%$6.75B$7.45B8.3923,822News CoveragePositive NewsGap DownRVMDRevolution Medicines4.478 of 5 stars$35.67-3.6%$69.92+96.0%-7.3%$6.67B$11.58M-7.93250News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.3046 of 5 stars$99.20-3.9%$101.57+2.4%+120.4%$6.59B$156.29M-32.96140News CoveragePositive NewsLEGNLegend Biotech3.5388 of 5 stars$34.60-2.7%$73.00+111.0%-40.5%$6.36B$627.24M-39.322,609Positive NewsABVXAbivax3.2554 of 5 stars$77.46+0.2%$92.33+19.2%+545.1%$5.85BN/A0.0061News CoveragePositive NewsShort Interest ↓RNAAvidity Biosciences3.0621 of 5 stars$45.27-2.3%$67.00+48.0%+7.3%$5.82B$10.90M-12.72190Positive NewsAXSMAxsome Therapeutics4.7654 of 5 stars$116.31-1.9%$178.00+53.0%+38.9%$5.80B$495.03M-22.94380Positive NewsAnalyst ForecastInsider TradeNUVLNuvalent3.2305 of 5 stars$74.05-2.7%$118.91+60.6%-9.7%$5.34BN/A-15.1140News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies CytomX Therapeutics Competitors Editas Medicine Competitors Grifols Competitors Revolution Medicines Competitors Rhythm Pharmaceuticals Competitors Legend Biotech Competitors Abivax Competitors Avidity Biosciences Competitors Axsome Therapeutics Competitors Nuvalent Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRPT) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SRPT Stock Alerts